Literature DB >> 23295065

Oral vaccination with an adenovirus-vectored vaccine protects against botulism.

Shan Chen1, Qingfu Xu, Mingtao Zeng.   

Abstract

We have previously shown that an adenovirus vectored vaccine delivered intramuscularly or intranasally was effective in protection against botulism in a mouse model. The adenoviral vector encodes a human codon-optimized heavy chain C-fragment (H(C)50) of botulinum neurotoxin type C (BoNT/C). Here, we evaluate the same vaccine candidate as an oral vaccine against BoNT/C in a mouse model. To elicit protective immunity, the mice were orally vaccinated with a single dose of 1×10(4) to 1×10(7)plaque forming units (pfu) of the adenoviral vector. The immune sera, collected six weeks after oral vaccination with 2×10(7)pfu adenovirus, have shown an ability to neutralize the biological activity of BoNT/C in vitro. Additionally, animals receiving a single dose of 2×10(6)pfu adenovirus or greater were completely protected against challenge with 100×MLD(50) of BoNT/C. The data demonstrated the feasibility to develop an adenovirus-based oral vaccine against botulism.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23295065      PMCID: PMC3614485          DOI: 10.1016/j.vaccine.2012.12.054

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  17 in total

1.  The complete nucleotide sequence of the gene coding for botulinum type C1 toxin in the C-ST phage genome.

Authors:  K Kimura; N Fujii; K Tsuzuki; T Murakami; T Indoh; N Yokosawa; K Takeshi; B Syuto; K Oguma
Journal:  Biochem Biophys Res Commun       Date:  1990-09-28       Impact factor: 3.575

2.  N-fragment of edema factor as a candidate antigen for immunization against anthrax.

Authors:  Mingtao Zeng; Qingfu Xu; Eric D Hesek; Michael E Pichichero
Journal:  Vaccine       Date:  2005-08-26       Impact factor: 3.641

3.  Intramuscular rather than oral administration of replication-defective adenoviral vaccine vector induces specific CD8+ T cell responses in the gut.

Authors:  S W Lin; A S Cun; K Harris-McCoy; H C Ertl
Journal:  Vaccine       Date:  2006-12-06       Impact factor: 3.641

4.  Rapid immune responses to a botulinum neurotoxin Hc subunit vaccine through in vivo targeting to antigen-presenting cells.

Authors:  David M White; Sabine Pellett; Mark A Jensen; William H Tepp; Eric A Johnson; Barry G W Arnason
Journal:  Infect Immun       Date:  2011-05-16       Impact factor: 3.441

5.  A single immunization with a recombinant canine adenovirus expressing the rabies virus G protein confers protective immunity against rabies in mice.

Authors:  Jianwei Li; Milosz Faber; Amy Papaneri; Marie-Luise Faber; James P McGettigan; Matthias J Schnell; Bernhard Dietzschold
Journal:  Virology       Date:  2006-08-30       Impact factor: 3.616

6.  Oral vaccination of mice with adenoviral vectors is not impaired by preexisting immunity to the vaccine carrier.

Authors:  Z Q Xiang; G P Gao; A Reyes-Sandoval; Y Li; J M Wilson; H C J Ertl
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.

Authors:  A Nowakowski; C Wang; D B Powers; P Amersdorfer; T J Smith; V A Montgomery; R Sheridan; R Blake; L A Smith; J D Marks
Journal:  Proc Natl Acad Sci U S A       Date:  2002-08-12       Impact factor: 11.205

8.  Purification, potency, and efficacy of the botulinum neurotoxin type A binding domain from Pichia pastoris as a recombinant vaccine candidate.

Authors:  M P Byrne; T J Smith; V A Montgomery; L A Smith
Journal:  Infect Immun       Date:  1998-10       Impact factor: 3.441

Review 9.  Botulinum neurotoxin vaccines: Past history and recent developments.

Authors:  Janice M Rusnak; Leonard A Smith
Journal:  Hum Vaccin       Date:  2009-12-01

10.  Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species.

Authors:  Stefano Colloca; Eleanor Barnes; Antonella Folgori; Virginia Ammendola; Stefania Capone; Agostino Cirillo; Loredana Siani; Mariarosaria Naddeo; Fabiana Grazioli; Maria Luisa Esposito; Maria Ambrosio; Angela Sparacino; Marta Bartiromo; Annalisa Meola; Kira Smith; Ayako Kurioka; Geraldine A O'Hara; Katie J Ewer; Nicholas Anagnostou; Carly Bliss; Adrian V S Hill; Cinzia Traboni; Paul Klenerman; Riccardo Cortese; Alfredo Nicosia
Journal:  Sci Transl Med       Date:  2012-01-04       Impact factor: 17.956

View more
  6 in total

1.  Induction of protective neutralizing antibody responses against botulinum neurotoxin serotype C using plasmid carried by PLGA nanoparticles.

Authors:  Tinashe B Ruwona; Haiyue Xu; Junwei Li; Diana Diaz-Arévalo; Amit Kumar; Mingtao Zeng; Zhengrong Cui
Journal:  Hum Vaccin Immunother       Date:  2016-02-02       Impact factor: 3.452

2.  Recombinant rabies virus particles presenting botulinum neurotoxin antigens elicit a protective humoral response in vivo.

Authors:  Andrew W Hudacek; Fetweh H Al-Saleem; Mallory Willet; Travis Eisemann; Jeffrey A Mattis; Lance L Simpson; Matthias J Schnell
Journal:  Mol Ther Methods Clin Dev       Date:  2014-10-01       Impact factor: 6.698

Review 3.  Noninvasive vaccination against infectious diseases.

Authors:  Zhichao Zheng; Diana Diaz-Arévalo; Hongbing Guan; Mingtao Zeng
Journal:  Hum Vaccin Immunother       Date:  2018-05-17       Impact factor: 3.452

Review 4.  Major pathogenic Clostridia in human and progress toward the clostridial vaccines.

Authors:  Lida Abdolmohammadi Khiav; Azadeh Zahmatkesh
Journal:  Iran J Basic Med Sci       Date:  2022-09       Impact factor: 2.532

Review 5.  Vaccines against Botulism.

Authors:  Grace Sundeen; Joseph T Barbieri
Journal:  Toxins (Basel)       Date:  2017-09-02       Impact factor: 4.546

Review 6.  Strategies to Develop a Mucosa-Targeting Vaccine against Emerging Infectious Diseases.

Authors:  Fengling Feng; Ziyu Wen; Jiaoshan Chen; Yue Yuan; Congcong Wang; Caijun Sun
Journal:  Viruses       Date:  2022-03-03       Impact factor: 5.048

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.